Orrick has advised European private equity firm Vitruvian Partners as the lead investor in Darktrace’s $50 million Series E financing round at a pre-money valuation of $1.6 billion.
A U.K.-based cyber defense firm, Darktrace’s technology is modeled on the human immune system and is the world’s leading, enterprise-grade AI with over 7,000 deployments worldwide. Existing investors Kohlberg Kravis Roberts and TenEleven Ventures also participated in the round.
The Orrick team was led by partner Ylan Steiner (Picture) and included associates Alex Gest, Michael Gale, Charles Baker and Candice O’Brien.
Law Firms: Orrick;
Clients: Vitruvian Partners;